Karyopharm Therapeutics Inc. — Form 10-Q
Filed August 13, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 52/100
What the filing says
Amendment No. 5 to the 2022 Equity Incentive Plan increased the share pool from an unspecified prior amount to 5,406,666 shares, effective May 22, 2026. Two template RSU agreements (Exhibits 10.3 and 10.4) document performance-vested grants tied to clinical milestones in selinexor development, with vesting contingent on achieving specified clinical objectives by December 31, 2027–2028, continued service, and stockholder approval of the expanded pool by May 31, 2027. Director compensation policy sets annual RSU grants at $125,000 fair value per director. No specific participant names, grant dates, or individual award amounts are disclosed in this exhibit package.
Why this rating
Share pool expansion is material relative to $37M market cap (~15% dilution risk), but vests only if clinical milestones achieved and stockholder approval obtained by May 2027—both uncertain. Moderate significance: real capital structure event but contingent and speculative.
See more from August 13, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.